Overview

A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and antitumor response of ramucirumab in combination with platinum/fluoropyrimidine regimens in Japanese participants with advanced gastric/gastrooesophageal junction cancer who have not received chemotherapy.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Antibodies, Monoclonal
Capecitabine
Cisplatin
Oxaliplatin
Ramucirumab